Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Petersen I. The morphological and molecular diagnosis of lung cancer. Dtsch Arztebl Int. 2011;108(31–32):525–531. doi:10.3238/arztebl.2011.0525
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597. doi:10.1200/jco.2004.08.163
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi:10.1056/NEJMoa011954
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thor Oncol. 2011;6(2):244–285. doi:10.1097/JTO.0b013e318206a221
   PubMed Web of Science ®Google Scholar
• Gerber DE. EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res. 2008;69(6):359–372. doi:10.1002/ddr.20268
   PubMed Web of Science ®Google Scholar
• Khan M, Lin J, Liao G, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2019;8:557. doi:10.3389/fonc.2018.00557
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008;99(11):1757–1762. PubMed PMID: 18985035; PubMed Central PMCID: PMCPMC2600690. doi:10.1038/sj.bjc.6604721
   PubMed Web of Science ®Google Scholar
• Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30(5):287–292. PubMed PMID: 21527061. doi:10.5732/cjc.011.10106
   PubMedGoogle Scholar
• Huang Z, Su W, Lu T, et al. First-line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress. Front Pharmacol. 2020;11:1591. doi:10.3389/fphar.2020.578091
   Web of Science ®Google Scholar
• Chicas-Sett R, Morales-Orue I, Castilla-Martinez J, et al. Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a systematic review. Int J Mol Sci. 2019;20(9):9. doi:10.3390/ijms20092173
   Web of Science ®Google Scholar
• Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–1618. doi:10.1200/jco.2017.76.2229
   PubMed Web of Science ®Google Scholar
• Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–356. doi:10.1038/nrclinonc.2011.58
   PubMed Web of Science ®Google Scholar
• Liao BC, Lin CC, Yang JC. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018;19(8):851–864. doi:10.1080/14656566.2018.1472765
   PubMed Web of Science ®Google Scholar
• Mehta MP, Aoyama H, Gondi V. The changing role of whole-brain radiotherapy: demise or time for selective usage? JAMA Oncol. 2017;3(8):1021–1022. PubMed PMID: 28056151. doi:10.1001/jamaoncol.2016.5414
   PubMed Web of Science ®Google Scholar
• Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):45–68. doi:10.1007/s11060-009-0073-4
   PubMed Web of Science ®Google Scholar
• Lippitz B, Lindquist C, Paddick I, Peterson D, O’Neill K, Beaney R. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev. 2014;40(1):48–59. doi:10.1016/j.ctrv.2013.05.002
   PubMed Web of Science ®Google Scholar
• Khan M, Lin J, Liao G, et al. Comparison of WBRT alone, SRS alone, and their combination in the treatment of one or more brain metastases: review and meta-analysis. Tumour Biol. 2017;39(7):1010428317702903. doi:10.1177/1010428317702903
   Google Scholar
• Barbour AB, Jacobs CD, Williamson H, et al. Radiation therapy practice patterns for brain metastases in the United States in the stereotactic radiosurgery era. Advan Rad Oncol. 2020;5(1):43–52. doi:10.1016/j.adro.2019.07.012
   PubMedGoogle Scholar
• Khan M, Arooj S, Li R, et al. Tumor primary site and histology subtypes role in radiotherapeutic management of brain metastases. Front Oncol. 2020;10:781. doi:10.3389/fonc.2020.00781
   PubMed Web of Science ®Google Scholar
• Angeli E, Nguyen TT, Janin A, Bousquet G. How to make anticancer drugs cross the blood–brain barrier to treat brain metastases. Int J Mol Sci. 2019;21(1):22. doi:10.3390/ijms21010022
   PubMed Web of Science ®Google Scholar
• Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 2013;82(2):282–287. PubMed PMID: 24021541. doi:10.1016/j.lungcan.2013.08.016
   PubMed Web of Science ®Google Scholar
• Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–631. PubMed PMID: 20595147. doi:10.1183/09031936.00195609
   PubMed Web of Science ®Google Scholar
• Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker Afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thor Oncol. 2015;10(1):156–163. PubMed PMID: 25247337; PubMed Central PMCID: PMCPMC4276567. doi:10.1097/jto.0000000000000380
   PubMed Web of Science ®Google Scholar
• Schuler M, Wu YL, Hirsh V, et al. First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thor Oncol. 2016;11(3):380–390. PubMed PMID: 26823294. doi:10.1016/j.jtho.2015.11.014
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JJ, Zhou C, et al. PL03.05: BRAIN: a Phase III trial comparing WBI and chemotherapy with Icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201). J Thor Oncol. 2017;12(1):S6. doi:10.1016/j.jtho.2016.11.007
   Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2016;376(7):629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34(24):2858–2865. PubMed PMID: 27022118. doi:10.1200/jco.2015.63.5888
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, Phase 3 study. Lancet (London, England). 2017;389(10072):917–929. PubMed PMID: 28126333. doi:10.1016/s0140-6736(17)30123-x
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global study. J Clin Oncol. 2016;34(7):661–668. PubMed PMID: 26598747. doi:10.1200/jco.2015.63.9443
   PubMed Web of Science ®Google Scholar
• Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter Phase II trial. J Clin Oncol. 2017;35(22):2490–2498. PubMed PMID: 28475456. doi:10.1200/jco.2016.71.5904
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi:10.1056/NEJMoa2027187
   PubMed Web of Science ®Google Scholar
• Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive non–small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021. doi:10.1001/jamaoncol.2021.3523
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK. Treatment of brain metastases in the modern genomic era. Pharmacol Ther. 2017;170:64–72. doi:10.1016/j.pharmthera.2016.10.011
   PubMed Web of Science ®Google Scholar
• Martínez P, Mak RH, Oxnard GR. Targeted Therapy as an alternative to whole-brain radiotherapy in EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases. JAMA Oncol. 2017;3(9):1274–1275. doi:10.1001/jamaoncol.2017.1047
   PubMed Web of Science ®Google Scholar
• Dudnik E, Yust-Katz S, Nechushtan H, et al. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer. 2016;98:114–117. doi:10.1016/j.lungcan.2016.05.031
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, Phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41. doi:10.1016/s1470-2045(16)30624-6)30624-6
   PubMed Web of Science ®Google Scholar
• Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a Phase II open-label study of atezolizumab in PD-L1-Selected patients with NSCLC. J Thor Oncol. 2018;13(11):1733–1742. doi:10.1016/j.jtho.2018.05.004
   PubMed Web of Science ®Google Scholar
• Gauvain C, Vauléon E, Chouaid C, et al. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer. 2018;116:62–66. doi:10.1016/j.lungcan.2017.12.008
   PubMed Web of Science ®Google Scholar
• Crinò L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2019;129:35–40. doi:10.1016/j.lungcan.2018.12.025
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, Phase 2 trial. Lancet Oncol. 2016;17(7):976–983. doi:10.1016/s1470-2045(16)30053-5
   PubMed Web of Science ®Google Scholar
• Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016;68:156–162. doi:10.1016/j.ejca.2016.09.013
   PubMed Web of Science ®Google Scholar
• Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys. 2016;95(2):673–679. doi:10.1016/j.ijrobp.2016.01.037
   PubMed Web of Science ®Google Scholar
• Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35(10):1070–1077. doi:10.1200/jco.2016.69.7144
   PubMed Web of Science ®Google Scholar
• Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management. Lung Cancer (Amsterdam, Netherlands). 2015;88(3):355–359. doi:10.1016/j.lungcan.2015.03.022
   PubMed Web of Science ®Google Scholar
• Mak KS, Gainor JF, Niemierko A, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015;17(2):296–302. doi:10.1093/neuonc/nou146
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. PubMed PMID: 28551359; PubMed Central PMCID: PMCPMC5538772. doi:10.1016/s1470-2045(17)30380-7
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Lukas RV, Goldschmidt J, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer (Amsterdam, Netherlands). 2019;128:105–112. PubMed PMID: 30642441. doi:10.1016/j.lungcan.2018.12.017
   PubMed Web of Science ®Google Scholar
• Patruni S, Khattab A, Abel S, et al. A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy. J Clin Oncol. 2019;37(15_suppl):9025. doi:10.1200/JCO.2019.37.15_suppl.9025
   Web of Science ®Google Scholar
• Hendriks LEL, Henon C, Auclin E, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thor Oncol. 2019;14(7):1244–1254. PubMed PMID: 30780002. doi:10.1016/j.jtho.2019.02.009
   PubMed Web of Science ®Google Scholar
• Shepard MJ, Xu Z, Donahue J, et al. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg. 2019:1–8. PubMed PMID: 31349225. doi:10.3171/2019.4.Jns19822
   PubMed Web of Science ®Google Scholar
• Singh C, Qian JM, Yu JB, Chiang VL. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. J Neurosurg. 2019;132(2):512–517. PubMed PMID: 30771783. doi:10.3171/2018.10.Jns181371
   PubMed Web of Science ®Google Scholar
• Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Rad Oncol Biol Phys. 2018;100(4):916–925. PubMed PMID: 29485071. doi:10.1016/j.ijrobp.2017.11.041
   PubMed Web of Science ®Google Scholar
• Pike LRG, Bang A, Ott P, et al. Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation. Radiother Oncol. 2017;124(1):98–103. PubMed PMID: 28662869. doi:10.1016/j.radonc.2017.06.006
   PubMed Web of Science ®Google Scholar
• Kotecha R, Kim JM, Miller JA, et al. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology. 2019;21(8):1060–1068. PubMed PMID: 30796838. doi:10.1093/neuonc/noz046
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. PubMed PMID: 24141714. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349. PubMed PMID: 18313558. doi:10.1016/j.jclinepi.2007.11.008
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. PubMed PMID: 19097774. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, Zheng T, Liao G. Lapatinib plus local radiation therapy for brain metastases from HER-2 positive breast cancer patients and role of trastuzumab: a systematic review and meta-analysis. Front Oncol. 2020;10:2315. doi:10.3389/fonc.2020.576926
   Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, Liao G. Impact of Tyrosine Kinase Inhibitors (TKIs) combined with radiation therapy for the management of brain metastases from renal cell carcinoma. Front Oncol. 2020;10:1246. doi:10.3389/fonc.2020.01246
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Kim S, Arrington J, et al. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017;133(2):331–338. PubMed PMID: 28466250. doi:10.1007/s11060-017-2437-5
   PubMed Web of Science ®Google Scholar
• Lesueur P, Escande A, Thariat J, et al. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC. Cancer Med. 2018;7(11):5505–5513. PubMed PMID: 30311424; PubMed Central PMCID: PMCPMC6247050. doi:10.1002/cam4.1825
   PubMed Web of Science ®Google Scholar
• Schapira E, Hubbeling H, Yeap BY, et al. Improved overall Survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys. 2018;101(3):624–629. PubMed PMID: 29678530. doi:10.1016/j.ijrobp.2018.02.175
   PubMed Web of Science ®Google Scholar
• Koenig JL, Shi S, Sborov K, et al. Adverse radiation effect and disease control in patients undergoing stereotactic radiosurgery and immune checkpoint inhibitor therapy for brain metastases. World Neurosurg. 2019;126:e1399–e411. PubMed PMID: 30902777. doi:10.1016/j.wneu.2019.03.110
   PubMed Web of Science ®Google Scholar
• Sprowls SA, Arsiwala TA, Bumgarner JR, et al. Improving CNS delivery to brain metastases by blood–tumor barrier disruption. Trends Cancer. 2019;5(8):495–505. doi:10.1016/j.trecan.2019.06.003
   PubMed Web of Science ®Google Scholar
• Gerber DE, Urbanic JJ, Langer C, et al. Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505). Clin Lung Cancer. 2017;18(3):333–339. PubMed PMID: 27923550; PubMed Central PMCID: PMCPMC5406261. doi:10.1016/j.cllc.2016.10.009
   PubMed Web of Science ®Google Scholar
• Iyengar P, Gerber DE. Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer j. 2013;19(3):247–262. PubMed PMID: 23708072. doi:10.1097/PPO.0b013e318292e51a
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. PubMed PMID: 25274032. doi:10.1158/0008-5472.Can-14-1258
   PubMed Web of Science ®Google Scholar
• Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine. 2018;97(33):e11936. doi:10.1097/md.0000000000011936
   PubMed Web of Science ®Google Scholar
• Sedgwick P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348:g1072. doi:10.1136/bmj.g1072
   Web of Science ®Google Scholar
• Wang G-Z, Zhang L, Zhao X-C, et al. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10(1):1125. doi:10.1038/s41467-019-08887-7
   PubMed Web of Science ®Google Scholar